Investment Thesis
Pre-revenue medical device company with $7M annual net losses and only $762K cash, implying critical 2-3 month funding runway. Despite 39% YoY loss improvement, the company faces severe liquidity risk without imminent revenue generation or capital raise. Fundamental business model remains unproven in electromedical apparatus sector.
Strengths
- Zero long-term debt - no leverage risk
- Net losses improving 38.9% YoY - suggests operational progress
- Minimal capex requirements - asset-light development model
Risks
- Critical cash position with ~2-3 months runway at current $5.2M burn rate
- Pre-revenue status with unvalidated commercialization pathway
- Severe negative profitability with -310.9% ROE and -182.4% ROA
- Imminent capital raise likely required, exposing shareholders to substantial dilution
- No demonstrated market traction or regulatory progress visibility
Key Metrics to Watch
- Monthly cash burn rate and remaining runway
- Clinical trial enrollment/regulatory milestone announcements
- Capital raise activity and dilution impact
- Revenue recognition or pre-revenue metrics (pilot programs, partnerships)
- Insider transaction patterns indicating confidence
Financial Metrics
Revenue
0.0
Net Income
-7.0M
EPS (Diluted)
$-8.93
Free Cash Flow
-5.2M
Total Assets
3.9M
Cash
762.4K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-310.9%
ROA
-182.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.29x
Quick Ratio
1.29x
Debt/Equity
0.00x
Debt/Assets
41.4%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T03:15:23.796849 |
Data as of: 2025-12-31 |
Powered by Claude AI